The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

by Fiona K. Middleton, John R. Pollard, Nicola J. Curtin
Published 2018-08-01

The TARC/sICAM5 ratio in patient plasma is a candidate biomarker for drug resistant epilepsy

by John R. Pollard, Ofer eEidelman, Gregory P. Mueller, Clifton L. Dalgard, Peter B. Crino, Christopher T. Anderson, Elizabeth J. Brand, Evren eBurakgazi-Dalkilic, Sai K. Ivaturi, Harvey B. Pollard
Published 2013-01-01

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

by Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón-Montaño, Tobias Koolmeister, Philip M. Reaper, Oliver Mortusewicz, Sylvain A. Jacques, Raoul V. Kuiper, Niklas Schultz, Martin Scobie, Peter A. Charlton, John R. Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday
Published 2016-12-01

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

by Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón-Montaño, Tobias Koolmeister, Philip M. Reaper, Oliver Mortusewicz, Sylvain A. Jacques, Raoul V. Kuiper, Niklas Schultz, Martin Scobie, Peter A. Charlton, John R. Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday
Published 2016-01-01

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

by Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Published 2016-12-01